DSS (DSS) Q1 2026 earnings summary

Executive summary

• Operates four business lines: Product Packaging, Biotechnology, Commercial Lending, and Securities & Investment Management, each at different stages of development and income generation.

• Total revenue for Q1 2026 was $4.33M, a 13% decrease year-over-year, with net loss widening to $6.35M from $5.30M in Q1 2025.

• Printed Product revenue grew 4% year-over-year, while Securities, Commercial Lending, and Biotechnology revenues declined sharply.

Financial highlights

• Q1 2026 revenue: $4.33M (down 13% YoY); net loss: $6.35M (vs. $5.30M loss in Q1 2025).

• Gross margin was negative, with cost of revenue ($5.53M) exceeding total revenue.

• Operating loss increased to $5.49M from $3.73M YoY.

• Stock-based compensation expense rose to $1.44M in Q1 2026, mainly at the Biotechnology subsidiary.

• Cash and cash equivalents at March 31, 2026: $4.94M.

Outlook and guidance

• Management expects continued focus on growing inventory/equipment loan portfolio and specialized lending.

• Cost reduction measures and cash burn control are ongoing to address going concern risks.